MX2011005118A - Composicion que comprende celulas madre mesenquimales o solucion de cultivo de celulas madre mesenquimales para la prevencion o tratamiento de enfermedades neurales. - Google Patents

Composicion que comprende celulas madre mesenquimales o solucion de cultivo de celulas madre mesenquimales para la prevencion o tratamiento de enfermedades neurales.

Info

Publication number
MX2011005118A
MX2011005118A MX2011005118A MX2011005118A MX2011005118A MX 2011005118 A MX2011005118 A MX 2011005118A MX 2011005118 A MX2011005118 A MX 2011005118A MX 2011005118 A MX2011005118 A MX 2011005118A MX 2011005118 A MX2011005118 A MX 2011005118A
Authority
MX
Mexico
Prior art keywords
stem cells
mesenchymal stem
prevention
treatment
culture solution
Prior art date
Application number
MX2011005118A
Other languages
English (en)
Inventor
Yoon-Sun Yang
Jong Wook Chang
Won Il Oh
Ju Yeon Kim
Original Assignee
Medipost Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medipost Co Ltd filed Critical Medipost Co Ltd
Publication of MX2011005118A publication Critical patent/MX2011005118A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/137—Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)

Abstract

Se proporciona una composición farmacéutica para la prevención y tratamiento de una enfermedad neural que incluye al menos uno seleccionado del grupo que consiste de células madre mesenquimales (MSC), una solución de cultivo de MSC, activina A, PF4, decorina, galectina 3, GDG15, glipicano, MFRP, ICAM5, IGFBP7, PDGG-AA, SPARCL1, trombospondina-1, WISP1, progranulina, IL-4, un factor que induce la expresión del mismo, y cualquiera de sus combinaciones y uno de sus métodos.
MX2011005118A 2008-11-14 2009-11-16 Composicion que comprende celulas madre mesenquimales o solucion de cultivo de celulas madre mesenquimales para la prevencion o tratamiento de enfermedades neurales. MX2011005118A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19329308P 2008-11-14 2008-11-14
KR20080113465 2008-11-14
KR1020090072114A KR20100054711A (ko) 2008-11-14 2009-08-05 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
KR1020090108662A KR20100054731A (ko) 2008-11-14 2009-11-11 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
PCT/KR2009/006712 WO2010056075A2 (en) 2008-11-14 2009-11-16 Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases

Publications (1)

Publication Number Publication Date
MX2011005118A true MX2011005118A (es) 2011-09-26

Family

ID=42279397

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011005118A MX2011005118A (es) 2008-11-14 2009-11-16 Composicion que comprende celulas madre mesenquimales o solucion de cultivo de celulas madre mesenquimales para la prevencion o tratamiento de enfermedades neurales.

Country Status (11)

Country Link
US (1) US10238692B2 (es)
EP (1) EP2365816B1 (es)
JP (2) JP5650122B2 (es)
KR (4) KR20100054711A (es)
CN (2) CN107412263A (es)
AU (1) AU2009314797B2 (es)
BR (1) BRPI0922022A2 (es)
CA (1) CA2743620C (es)
MX (1) MX2011005118A (es)
MY (1) MY179052A (es)
WO (1) WO2010056075A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005496A (es) 2006-11-30 2009-06-03 Medipost Co Ltd Uso de una composicion que contiene una celula madre mesenquimal derivada de sangre del cordon umbilical humano para inducir diferenciacion y proliferacion de celulas precursoras neurales o celulas madre neurales a celulas neurales.
US9358320B2 (en) 2008-04-25 2016-06-07 Allosource Multi-layer tissue patches
US9480549B2 (en) 2008-04-25 2016-11-01 Allosource Multi-layer tissue patches
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
WO2011106476A1 (en) * 2010-02-25 2011-09-01 Abt Holding Company Modulation of microglia activation
WO2012060517A1 (ko) * 2010-11-05 2012-05-10 하이스템(주) Ｃｄ45가 발현되는 중간엽 줄기세포를 유효성분으로 포함하는 신경질환 예방 및 치료용 의약 조성
US20150352185A1 (en) * 2010-11-16 2015-12-10 Denis G. Kay Method for increasing neprilysin expression and activity
KR101615161B1 (ko) * 2011-02-02 2016-04-25 메디포스트(주) 신경질환의 예방 또는 치료를 위한 icam-1의 용도
WO2012164137A1 (es) 2011-05-30 2012-12-06 Fundación Investigación En Regeneración Del Sistema Nervioso Células madre y células de la estirpe neural derivadas de la glía envolvente olfatoria, y sus aplicaciones
US9950016B2 (en) * 2011-06-24 2018-04-24 National University Of Ireland, Galway Cell secreted proteins for the treatment of myocardial infarction
WO2013039000A1 (ja) * 2011-09-13 2013-03-21 Ochiya Takahiro アルツハイマー病の予防または治療のための医薬品
CN103087983A (zh) * 2011-10-27 2013-05-08 北京清美联创干细胞科技有限公司 一种药物诱导肌肉间充质干细胞增殖和分化的方法及应用
US9162011B2 (en) 2011-12-19 2015-10-20 Allosource Flowable matrix compositions and methods
KR20130104924A (ko) * 2012-03-16 2013-09-25 (주)히스토스템 항바이러스 작용을 갖는 제대혈 다분화능 줄기세포 유래의 세포활성화 물질을 포함하는 조성물 및 이의 제조방법
EP2659897A1 (en) * 2012-05-02 2013-11-06 Philipps-Universität Marburg Stem cell derived composition for the treatment of acute injury and degenerative diseases
EP2959909B1 (en) * 2013-02-20 2019-12-18 Samsung Life Public Welfare Foundation Composition for treating inflammatory brain diseases which includes stem cell as active ingredient
AU2014248873B2 (en) 2013-03-13 2017-03-23 Allosource Fascia fibrous compositions and methods for their use and manufacture
EP2970882B1 (en) 2013-03-15 2018-11-28 AlloSource Cell repopulated collagen matrix for soft tissue repair and regeneration
WO2014141219A1 (en) * 2013-03-15 2014-09-18 Blue Horizon International Llc Umbilical cord blood derived stem cell transplantation for the treatment of neural disorder
US20140286910A1 (en) * 2013-03-19 2014-09-25 Nikolai Tankovich Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity
KR101455933B1 (ko) * 2013-05-28 2014-10-31 가톨릭대학교 산학협력단 인간골수유래 중간엽줄기세포와 미노사이클린 병용투여를 통한 다발성경화증 치료제 및 치료방법
CN103599129A (zh) * 2013-11-07 2014-02-26 唐明淇 一种人干细胞组合物在制备用于治疗阿尔茨海默症的药物中的用途
US9795707B2 (en) 2013-12-06 2017-10-24 Allosource Methods of drying sheets of donor-provided human birth tissue
US20160143950A1 (en) * 2013-12-22 2016-05-26 Nikolai Tankovich Stem cells and stem cell factors for inhibiting the progression of alzheimer's disease
CN103751228B (zh) * 2014-01-27 2016-04-20 贵州神奇药物研究院 治疗老年痴呆的药物及其制备方法
CN104758923A (zh) * 2015-03-11 2015-07-08 黑龙江天晴干细胞股份有限公司 一种治疗神经损伤的干细胞制剂及其制备方法
EP3342858B1 (en) 2015-08-28 2023-10-04 Rohto Pharmaceutical Co., Ltd. Ror1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ror1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating diseases by using ror1-positive mesenchymal stem cells
JP7108537B2 (ja) * 2016-04-27 2022-07-28 ロート製薬株式会社 Ｃｄ２０１、ｃｄ４６、ｃｄ５６、ｃｄ１４７及びｃｄ１６５からなる群より選択される少なくとも１種の細胞表面マーカーを発現する間葉系幹細胞及びその調製方法、並びに上記間葉系幹細胞を含む医薬組成物及びその調製方法
IL299420A (en) 2016-04-28 2023-02-01 Nipro Corp synapse producing substance
IL264825B (en) * 2016-08-14 2022-08-01 Univ Ramot Exosomes from mesenchymal cells for the treatment of neurological diseases
US10772986B2 (en) 2017-01-26 2020-09-15 Allosource Fascia fibrous compositions and methods for their use and manufacture
JP7082372B2 (ja) 2017-02-15 2022-06-08 ロート製薬株式会社 肺線維症治療剤、ｐｔｐｒｒ発現促進剤及び肺線維症治療用キット
CN116590227A (zh) 2017-03-03 2023-08-15 日本乐敦制药株式会社 间充质干细胞和肝疾病治疗剂
EP3591038A4 (en) 2017-03-03 2020-11-25 Rohto Pharmaceutical Co., Ltd. MESENCHYMATIC STEM CELL, AND PHARMACEUTICAL COMPOSITION
US20200069740A1 (en) 2017-03-08 2020-03-05 Rohto Pharmaceutical Co., Ltd. Ror1-positive mesenchymal stem cell-containing pharmaceutical composition for preventing or treating disease associated with fibrosis, method for preparing same, and method for preventing or treating disease associated with fibrosis using ror1-positive mesenchymal stem cells
EP3636271A4 (en) 2017-06-09 2021-03-03 Osaka University THERAPEUTIC FOR DILATED CARDIOMYOPATHY
CN107320495A (zh) * 2017-06-19 2017-11-07 北正赛欧（北京）生物科技有限公司 用于促进细胞损伤修复的组合物及其应用
JP7391327B2 (ja) 2018-01-12 2023-12-05 国立大学法人大阪大学 重層扁平上皮細胞の正常分化・成熟促進剤、上皮疾患治療剤及び重層扁平上皮細胞の正常分化・成熟促進方法
KR102053868B1 (ko) 2018-01-31 2020-01-22 가톨릭대학교 산학협력단 하비갑개 유래 중간엽 줄기세포를 유효성분으로 포함하는 퇴행성 신경계질환 예방 또는 치료용 약학적 조성물
GB201803010D0 (en) * 2018-02-26 2018-04-11 Royal Holloway & Bedford New College Neurodegenerative disorders
WO2019203555A1 (ko) * 2018-04-17 2019-10-24 한국생명공학연구원 Ｐｒｏｇｒａｎｕｌｉｎ 단백질을 포함하는 간질환의 예방 또는 치료용 조성물
US20210220340A1 (en) 2018-06-21 2021-07-22 The Asan Foundation Composition for prevention or treatment of neurodegenerative disease
CN109182260A (zh) * 2018-09-11 2019-01-11 邵勇 一种体外培养胎膜间充质干细胞的方法
WO2020181411A1 (zh) * 2019-03-08 2020-09-17 玛旺干细胞医学生物科技股份有限公司 间充质干细胞在预防或治疗情绪疾病上的医药用途
CN111635886A (zh) * 2020-07-02 2020-09-08 成都恩喜医疗管理有限公司 一种间充质干细胞的制备方法与应用
AU2021340971A1 (en) * 2020-09-08 2023-03-30 Longeveron, Inc. Treatment of Alzheimer's disease with allogeneic mesenchymal stem cells
KR20230128452A (ko) * 2020-10-26 2023-09-05 하다지트 메디칼 리서치 써비시즈 앤드 디벨롭먼트 리미티드 중간엽 줄기 세포 및 이의 배양
WO2022176735A1 (ja) 2021-02-22 2022-08-25 ロート製薬株式会社 糖尿病の予防及び／又は治療剤
WO2023054918A1 (ko) * 2021-09-30 2023-04-06 주식회사 디자인셀 네프릴라이신을 과발현하는 줄기세포, 이의 배양액 및 이들로부터 분리된 엑소좀을 유효성분으로 포함하는 인지기능장애의 예방 또는 치료용 약학적 조성물
WO2023080413A1 (ko) 2021-11-02 2023-05-11 주식회사 디자인셀 줄기세포 배양액 및 이로부터 분리된 엑소좀을 유효성분으로 포함하는 안구 질환의 예방 또는 치료용 약학적 조성물
JPWO2023140347A1 (es) 2022-01-24 2023-07-27
JPWO2023140348A1 (es) 2022-01-24 2023-07-27
WO2023154953A1 (en) * 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN115192609A (zh) * 2022-05-10 2022-10-18 湖南中南大学湘雅口腔医院 间充质干细胞在制备治疗抑郁症的药物中的应用
CN116115738B (zh) * 2023-02-22 2024-09-03 重庆大学 细胞因子Igfbp7在制备治疗小鼠老年性肌肉萎缩的药物中的应用
CN117547597A (zh) * 2023-11-28 2024-02-13 四川大学华西医院 基因Wisp1在制备调控MSCs抗衰老表型药物中的应用
CN117384857B (zh) * 2023-12-08 2024-03-19 上海兴瑞一达生物科技有限公司 一种pf4基因修饰的间充质干细胞外泌体及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8013A (en) * 1851-04-01 Improvement in wheat-fans
US7354588B1 (en) 1987-05-04 2008-04-08 Dana Farber Cancer Institute Functional derivatives of ICAM-1 with altered ability to bind LFA-1 or HRV
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US20030060398A1 (en) * 1997-09-19 2003-03-27 Gluckman Peter David Neuronal rescue agent
US5837576A (en) 1997-10-31 1998-11-17 Vanguard International Semiconductor Corporation Method for forming a capacitor using a silicon oxynitride etching stop layer
US6900299B1 (en) 1999-03-11 2005-05-31 University Of South Florida Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection
PT1621208E (pt) 1999-03-12 2010-04-07 Univ Leland Stanford Junior Vacinação com adn para tratamento de doença auto-imune
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
DE60032355T2 (de) * 1999-05-17 2007-04-26 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh NEUROPROTEKTIVE EIGENSCHAFTEN VON GDF-15, EINEM VERTRETER DER TGF-ß-SUPERFAMILIE
US20040208858A1 (en) 2000-04-12 2004-10-21 Gihan Tennekoon Therapeutic uses for mesenchymal stromal cells
KR100947577B1 (ko) 2000-06-26 2010-03-15 엔씨 메디컬 리서치 가부시키가이샤 신경계 세포로 분화할 수 있는 세포를 포함하는 세포분획
US20040037775A1 (en) 2000-08-01 2004-02-26 Siahaan Teruna J. Leukocyte internalized peptide-drug conjugates
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
KR100449141B1 (ko) 2001-04-19 2004-09-21 (주)라이프코드 간엽 간세포를 신경세포로 분화시키는 방법
KR100489248B1 (ko) 2002-02-19 2005-05-11 메디포스트(주) 제대혈 유래 간엽줄기세포ㆍ전구세포의 분리배양방법 및간엽조직으로의 분화유도방법
US20090192105A1 (en) 2002-02-20 2009-07-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
AU2003252559A1 (en) 2002-08-17 2004-03-03 Hae-Young Suh A method for transdifferentiating mesenchymal stem cells into neuronal cells
US20040203142A1 (en) 2003-04-14 2004-10-14 Reliance Life Sciences Pvt. Ltd. Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation thereof for therapeutic purposes
ATE505539T1 (de) 2003-09-09 2011-04-15 Univ Keio Verfahren zur förderung des überlebens und/oder der proliferation einer neuralen stammzelle und zur förderung der neuritenverlängerung, promotor dafür, die neurale stammzelle enthaltende pharmazeutische zusammensetzung, testverfahren und screening-verfahren
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
JP4027359B2 (ja) 2003-12-25 2007-12-26 キヤノン株式会社 マイクロ揺動体、光偏向器、画像形成装置
EP2298862B1 (en) * 2004-03-22 2017-08-30 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
EP1767617A1 (en) 2005-09-26 2007-03-28 Letizia Mazzini Mesenchymal stem cells isolation and expansion method and uses thereof
EP1951665A1 (en) 2005-11-14 2008-08-06 Dominion Pharmakine S.L. Novel inhibitors of the lfa-1/icam-1 interaction, and uses thereof
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
KR100792184B1 (ko) 2006-05-12 2008-01-07 재단법인서울대학교산학협력재단 개의 제대혈, 태반 및 개 태아의 심장 유래 다분화능 성체줄기세포, 그 제조방법 및 이를 함유하는 세포 치료제
KR20080049562A (ko) * 2006-11-30 2008-06-04 가톨릭대학교 산학협력단 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는 신경손상 질환 치료제
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
JP2014240388A (ja) 2014-12-25
KR20100054759A (ko) 2010-05-25
AU2009314797A1 (en) 2010-05-20
KR20110087263A (ko) 2011-08-02
US20110262393A1 (en) 2011-10-27
CN102281883A (zh) 2011-12-14
KR101533989B1 (ko) 2015-07-06
BRPI0922022A2 (pt) 2017-07-11
AU2009314797B2 (en) 2012-10-11
JP5893084B2 (ja) 2016-03-23
US10238692B2 (en) 2019-03-26
CA2743620C (en) 2017-08-15
KR20100054711A (ko) 2010-05-25
WO2010056075A2 (en) 2010-05-20
CA2743620A1 (en) 2010-05-20
JP5650122B2 (ja) 2015-01-07
KR20100054731A (ko) 2010-05-25
WO2010056075A3 (en) 2010-09-30
JP2012508733A (ja) 2012-04-12
EP2365816A4 (en) 2013-05-15
MY179052A (en) 2020-10-26
KR101114800B1 (ko) 2012-03-13
EP2365816B1 (en) 2017-06-28
EP2365816A2 (en) 2011-09-21
CN107412263A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
MY179052A (en) Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases
WO2011020120A3 (en) Multi-transgenic pigs for diabetes treatment
WO2011090741A3 (en) TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
WO2009009620A3 (en) Acellular tissue matrix compositions for tissue repair
CY1120115T1 (el) Προερχομενα απο μυελο των οστων μεσεγχυματικα αρχεγονα κυτταρα ως μια πηγη νευρικων προγονων
NZ595854A (en) Methods and compositions for treatment of bone defects with placental cell populations (ELOVL2, ST3GAL6, STGALNAC5, SLC12A8)
MX348735B (es) Celulas madre mesenquimales que expresan los receptores tnf-alfa.
WO2011090740A3 (en) Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
WO2007100692A3 (en) Method of generating human retinal progenitors from embryonic stem cells
TW200637522A (en) Skin treatment articles and methods
WO2010138806A3 (en) Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
IN2014DN10390A (es)
MX2011009752A (es) Tratamiento de enfermedades relacionadas a homologo tipo delta 1(dlk1) por inhibicion de transcrito antisentido natural a homologo tipo delta (dlk1).
WO2011079263A3 (en) Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
EP1907014A4 (en) CHONDROGENIC COMPOSITIONS AND METHODS OF USE
Dang et al. Human Chondrocytes from Human Adipose Tissue‐Derived Mesenchymal Stem Cells Seeded on a Dermal‐Derived Collagen Matrix Sheet: Our Preliminary Results for a Ready to Go Biotechnological Cartilage Graft in Clinical Practice
TN2012000157A1 (en) Treatment using reprogrammed mature adult cells
EP3252068A3 (en) Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2011017516A3 (en) Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
WO2008003656A3 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
WO2014165723A3 (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
WO2006032054A3 (en) Differentiation of human mesenchymal stem cells to cardiac progenitor cells that promote cardiac repair
MX2009003553A (es) Uso de goma arabiga para mejorar el crecimiento y supervivencia de bifidobacteria.
WO2011066082A3 (en) Markers associated with ribavirin-induced anemia
EP1970078A4 (en) COMPOSITION FOR INHIBITING A TARGET GENE IN AN EYEBORN AND REMEDY FOR ACAPIC DISEASE

Legal Events

Date Code Title Description
FG Grant or registration